Showing 6631-6640 of 7495 results for "".
- Forging Ahead For Clear-Cut Best Practices for MOHS Surgeryhttps://practicaldermatology.com/news/forging-ahead-for-clear-cut-best-practices-for-mohs-surgery/2458204/New research on the average number of surgical slices made during Mohs micrographic surgery (MMS) will serve as a first step towards identifying best practices for MMS, as well as identifying and informing physicians who may need re-training because their practice patterns deviate far from their
- Allergan Officially Adds Coolsculpting to Portfoliohttps://practicaldermatology.com/news/allergan-adds-coolsculpting-to-portfolio/2458207/It’s a done deal. Allergan now owns ZELTIQ® Aesthetics. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting h
- RxPhoto Releases Updated HIPPA-Compliant Mobile Clinical Photography Apphttps://practicaldermatology.com/news/rxphoto-releases-updated-mobile-hippa-compliant-clinical-photo-app/2458213/RxPhoto has released version 3 of its mobile medical photography solution for medical practices and providers. Medical practices can now remain HIPAA compliant while using their mobile devices to securely capture, manage and share medical photos and videos.
- AAD, Other Major Medical Associations Support March For Sciencehttps://practicaldermatology.com/news/aad-other-major-medical-associations-support-march-for-science/2458214/The American Academy of Dermatology is joining up with many leading organizations in support of the March for Science and its nonpartisan call for the appreciation of scientific evidence, education, and investment. There are close to
- White (But Not Red) Wine Linked to Rosaceahttps://practicaldermatology.com/news/white-but-not-red-wine-linked-to-rosacaea/2458216/White wine and liquor may increase rosacea risk, according to a new study in the Journal of the Amer
- BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soonhttps://practicaldermatology.com/news/biopharmx-completes-phase-2b-trial-of-bpx-01-topline-results-coming-soon/2458217/BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now plans to announce topline data from the trial in the fi
- EWG Surveys Personal Care Product Companies About Removing 1,4-Dioxanehttps://practicaldermatology.com/news/ewg-surveys-personal-care-product-companies-about-removing-14-dioxane/2458220/The Environmental Working Group (EWG) is surveying U.S. makers of personal care products to ask if they are working to remove 1,4-dioxane, a potential human carcinogen, from their products. At least 8,000 products on the market contain ethoxylated ingredie
- Novan: Positive Topline Results with Fungicidal SB208 in Phase 2 Trialhttps://practicaldermatology.com/news/nolan-positive-topline-results-with-fungicidal-sb208-in-phase-2-trial/2458222/Novan, Inc. has announced positive topline results from their Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. Novan’s SB208 Gel, at bo
- Business News: Allergan and ZELTIQ Announce Expiration of HSR Waiting Period for Pending Transactionhttps://practicaldermatology.com/news/business-news-allergan-and-zeltiq-announce-expiration-of-hsr-waiting-period-for-pending-transaction/2458225/Allergan is now one step closer to officially acquiring Zeltiq. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired with respect to Allergan's proposed acquisition of ZELTIQ.
- Scary Findings About Common Dermatologic Features of Classic Movie Villainshttps://practicaldermatology.com/news/study-ids-scary-findings-about-common-dermatologic-features-of-classic-movie-villains/2458227/What makes a villain (besides malice)? Scars, warts, deep wrinkles and alopecia, according to a new study that sought to identify the common dermatologic features of classic movie villains including Dr. Hannibal Lecter (“The Silence of the Lambs,” 1991), Mr. Potter (“It&